Drugs / JAB-23E73
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07640295 | Jun 2026 → Dec 2029 expected | pancreatic ductal adenocarcinoma | Jacobio Pharmaceuticals Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06973564 | May 2025 → Nov 2027 expected | cancer | Jacobio Pharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06959615 | Nov 2024 → Dec 2026 expected | neoplasm | Jacobio Pharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JAB-23E73 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06973564 ↗ |
| Action | Inhibit | “pan-KRAS inhibitor JAB-23E73” NCT06959615 ↗ |
| Route | Oral | “Administered orally” NCT06959615 ↗ |
| Target | KRAS | “pan-KRAS inhibitor JAB-23E73” NCT06959615 ↗ |